XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.3
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Feb. 28, 2023
May 17, 2022
Dec. 20, 2018
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Interest income       $ 110,596 $ 55,715 $ 555,281 $ 180,813  
Principal repayments           118,847 71,172  
Outstanding principal balance               $ 5,017,987
Accrued interest       82,500   82,500   275,547
Accounts receivable balance       25,591,342   25,591,342   23,084,000
Prepaid expenses and other current assets - related party       3,047,669   3,047,669   1,967,527
Revenue       12,823,797 12,016,098 37,537,003 38,296,402  
Grigorios Siokas [Member]                
Borrowing     $ 1,718,400          
Outstanding principal balance       12,684   12,684   12,821
Foreign curreny translation           137    
Accrued interest       973   973   206,355
Interest rate     4.70%          
Maturity date     Mar. 18, 2019          
Cana Holdings Laboratories Holding Limited [Member]                
Secured promissory note $ 4,457,520              
Description related to interest on principal Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus 1 month LIBOR per annum (5.18% as of September 30, 2023)              
Maturity of promissory note 5 days              
Interest income $ 148,789     112,292        
DOC Pharma S.A. [Member]                
Interest income           174,798    
Principal repayments           317,520    
Interest repayments           172,812    
Prepaid expenses           $ 7,599,545    
Interest rate           5.50%    
Loan term           10 days    
Maturity date           Dec. 01, 2032    
Accounts payable and accrued expenses - related party       1,536   $ 1,536   201,991
Prepaid balance       4,279,200   4,279,200    
Accounts receivable - related party       1,981,814   1,981,814   2,070,570
Prepaid expenses and other current assets - related party       5,493,826   5,493,826   3,320,345
Revenue       40,885 401,179 $ 43,287 819,896  
Agreement terminate           Dec. 31, 2025    
Pieces per product           1,000 pieces    
Purchased of additional licenses           $ 449,185    
Loan current portion       423,360   423,360   427,720
Loan non-current portion       3,492,720   3,492,720   3,851,280
Inventroy purchase       456,948 412,216 1,057,621 1,672,002  
Description of research and development   The total cost of this project will be €1,425,000 plus VAT and will be done over three phases as follows: Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). SkyPharm has bought a total of as of 81 licenses at value of €554,500 ($593,204) which is 38.91% of the total cost, as of December 31, 2022            
Purchase of branded pharmaceuticals $ 1,965,600              
Monthly basis instalments           35,660    
DOC Pharma S.A. [Member] | Inventories Related Agreement [Member]                
Inventroy purchase       455,586 450,311 1,048,557 1,127,897  
Dimitrios Goulielmos [Member]                
Outstanding principal balance       10,796   10,796   10,912
Foreign curreny translation           116    
Panagiotis Kozaris [Member]                
Shares owned           51,159 0  
Prepaid expenses       194,215   194,215   143,056
Maria Kozari [Member]                
Accounts receivable balance       1,009,103   1,009,103   760,025
Net sales       122,969 $ 115,625 359,760 $ 328,017  
George Terzis [Member]                
Unpaid salaries and bonuses       95,000   95,000    
Kanarogloy & Sia Epe [Member]                
Accounts payable and accrued expenses - related party       $ 6,326   $ 6,326   $ 11,927